Smolen JS, Landewé R, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3–18. https://doi.org/10.1136/ard-2022-223356.
Article CAS PubMed Google Scholar
Verhoeven MMP, Welsing PMJ, Bijlsma JWJ, et al. Effectiveness of remission induction strategies for early rheumatoid arthritis: a systematic literature review. Curr Rheumatol Rep. 2019;21:24. https://doi.org/10.1007/s11926-019-0821-1.
Article CAS PubMed PubMed Central Google Scholar
Hamann P, Holland R, Hyrich K, et al. Factors associated with sustained remission in rheumatoid arthritis in patients treated with anti-tumor necrosis factor. Arthritis Care Res (Hoboken). 2017;69(6):783–93. https://doi.org/10.1002/acr.23016.
Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskel Dis. 2017;9(10):249–62. https://doi.org/10.1177/1759720X17720366.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis a review. JAMA. 2018;320(13):1360–72. https://doi.org/10.1001/jama.2018.13103.
Ten Cate DF, Luime JJ, Swen N, et al. Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis - a systematic review of the literature. Arthritis Res Ther. 2013;15(1):R4. https://doi.org/10.1186/ar4132.
Article PubMed PubMed Central Google Scholar
Kawashiri SY, Suzuki T, Nakashima Y, et al. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. Rheumatology (Oxford). 2014;53:562–9. https://doi.org/10.1093/rheumatology/ket405.
Ozgocmen S, Ozdemir H, Kiris A, et al. Clinical evaluation and power Doppler sonography in rheumatoid arthritis: evidence for ongoing synovial inflammation in clinical remission. South Med J. 2008;101(3):240–5. https://doi.org/10.1097/SMJ.0b013e318164e16a.
Saleem B, Brown AK, Keen H, et al. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis. 2011;70:792–8. https://doi.org/10.1136/ard.2010.134445.
Ben Abdelghani K, Miladi S, Souabni L, et al. Role of ultrasound in assessing remission in rheumatoid arthritis. Diagn Intervent Imaging. 2015;96:3–10. https://doi.org/10.1016/j.diii.2014.07.006.
Elkhouly T, Elnady BM, Rageh EMH. Validity of Doppler subclinical synovitis as an activity marker associated with bone erosions in rheumatoid arthritis patients during clinical remission. Egypt J Radiol Nuclear Med. 2016;47:985–90. https://doi.org/10.1136/annrheumdis-2020-eular.2059.
Naredo E, Bonilla G, Gamero F, et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis. 2005;64:375–81. https://doi.org/10.1136/ard.2004.023929.
Article CAS PubMed PubMed Central Google Scholar
Dougados M, Jousse-Joulin S, Mistretta F, et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis. 2010;69:828–33. https://doi.org/10.1136/ard.2009.115493.
Mandl P, Kurucz R, Niedermayer D, et al. Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects. Rheumatology (Oxford). 2014;53:2136–42. https://doi.org/10.1093/rheumatology/keu211.
Terslev L, von der Recke P, Torp-Pedersen S, et al. Diagnostic sensitivity and specificity of Doppler ultrasound in rheumatoid arthritis. J Rheumatol. 2008;35:49–53.
Filippucci E, Iagnocco A, Salaffi F, et al. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis. 2006;65:1433–7. https://doi.org/10.1136/ard.2005.044628.
Article CAS PubMed PubMed Central Google Scholar
Naredo E, Moller I, Cruz A, et al. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:2248–56. https://doi.org/10.1002/art.23682.
Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72:804–14. https://doi.org/10.1136/annrheumdis-2012-203158.
Naredo E, Valor L, De La Torre I, et al. Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed? Arthritis Care Res (Hoboken). 2013;65:512–7. https://doi.org/10.1002/acr.21869.
Janta I, Valor L, De La Torre I, et al. Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: which joints and tendons should be assessed to predict unstable remission? Rheumatol Int. 2016;36:387–96. https://doi.org/10.1007/s00296-015-3409-8.
Article CAS PubMed Google Scholar
Rosa J, Ruta S, Saucedo C, et al. Does a simplified 6-joint ultrasound index correlate well enough with the 28-joint disease activity score to be used in clinical practice? J Clin Rheumatol. 2016;22:179–83. https://doi.org/10.1097/RHU.0000000000000415.
De Miguel E, Pecondón-Español A, Castaño-Sánchez M, et al. A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. Rheumatol Int. 2017;37:1347–56. https://doi.org/10.1007/s00296-017-3714-5.
Aydin SZ, Gunal EK, Ozata M, et al. Six joint ultrasound in rheumatoid arthritis: a feasible approach for implementing ultrasound in remission. Clin Exp Rheumatol. 2017;35:853–6.
Silvagni E, Zandonella Callegher S, Mauric E, et al. Musculoskeletal ultrasound for treating rheumatoid arthritis to target—a systematic literature review. Rheumatology. 2022;61:4590–602.
Article PubMed PubMed Central Google Scholar
Picchianti Diamanti A, Navarini L, Messina F, et al. Ultrasound detection of subclinical synovitis in rheumatoid arthritis patients in clinical remission: a new reduced-joint assessment in 3 target joints. Clin Exp Rheumatol. 2018;36(6):984–9.
Mohamed MF, Beck D, Camp S, et al. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol. 2020;60(2):188–97. https://doi.org/10.1002/jcph.1513.
Article CAS PubMed Google Scholar
McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21:183. https://doi.org/10.1186/s13075-019-1964-1.
Article PubMed PubMed Central Google Scholar
Strand V, Schiff M, Tundia N, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21:263. https://doi.org/10.1186/s13075-019-2059-8.
Article CAS PubMed PubMed Central Google Scholar
Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–800. https://doi.org/10.1002/art.41032.
Article CAS PubMed Google Scholar
Burmester GR, Kremer JM, Van de Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–12.
Comments (0)